Tao et al. demonstrated the feasibility of using ovarian cancer organoids to predict PARP inhibitor responses in a small patient cohort [73], while Sheta et al. generated 3D organoids from cancer cells of HGSC patients and identified distinct gene expression differences between PARP-sensitive and PARP-resistant organoids [79]. The gene discussed is PARP1; the disease is ovarian cancer.